Back to Home

Introducing Our New Principal Investigator — Dr. Dimitrios Tsoukas

June 2, 2025

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon
View as PDF

Introducing Our New Principal Investigator — Dr. Dimitrios Tsoukas

June 9, 2025

RegenMed is proud to announce that Dr. Dimitrios Tsoukas will act as Principal Investigator for a series of major Physicians-Owned Circles in the fast-evolving field of orthobioligics.  These will be the first POCs in Greece.  The initial POC Observational Protocol designed by Dr. Tsoukas will generate clinically and statistically significant datasets comparing safety and efficacy of PRP, ADSCs, and BMAC in knee osteoarthritis.  His clinical surveys will not only track dosage, injection sites and other key treatment protocol information, but specific products used and delivery approaches.  

The resulting well-correlated datasets will thus represent substantial value to product manufacturers, payers, researchers, AI models and other licensees.  Physician investigators participating in Dr. Tsoukas’s POCs will share 85% of all such license fees.  

In addition to senior positions in several orthopedic organizations such as ESSKA and ISAKOS, Dr. Tsoukas is the founder of IARMES, which includes other leading orthopedic practitioners in Europe and North America.  Moreover, Dr. Tsoukas also teaches and practices in several countries outside of Greece, including Switzerland, Qatar, and the UAE.  He is also an Adjunct Professor at the University of Nebraska, Lincoln.  As such, RegenMed and Dr. Tsoukas expect to significantly expand international physician participation in his Circles.

‍

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Introducing Our New Principal Investigator — Dr. Dimitrios Tsoukas

June 2, 2025

RegenMed is proud to announce that Dr. Dimitrios Tsoukas will act as Principal Investigator for a series of major Physicians-Owned Circles in the fast-evolving field of orthobioligics.  These will be the first POCs in Greece.  The initial POC Observational Protocol designed by Dr. Tsoukas will generate clinically and statistically significant datasets comparing safety and efficacy of PRP, ADSCs, and BMAC in knee osteoarthritis.  His clinical surveys will not only track dosage, injection sites and other key treatment protocol information, but specific products used and delivery approaches.  

The resulting well-correlated datasets will thus represent substantial value to product manufacturers, payers, researchers, AI models and other licensees.  Physician investigators participating in Dr. Tsoukas’s POCs will share 85% of all such license fees.  

In addition to senior positions in several orthopedic organizations such as ESSKA and ISAKOS, Dr. Tsoukas is the founder of IARMES, which includes other leading orthopedic practitioners in Europe and North America.  Moreover, Dr. Tsoukas also teaches and practices in several countries outside of Greece, including Switzerland, Qatar, and the UAE.  He is also an Adjunct Professor at the University of Nebraska, Lincoln.  As such, RegenMed and Dr. Tsoukas expect to significantly expand international physician participation in his Circles.

‍

Share This Page
Facebook Logo
Twitter Logo
Linkedin Logo
Email Icon

Read The Latest

June 26, 2025

Invest in the Future: Webinar with Our CEO and Co-Founder

Discover the incredible growth potential of our company! Join our CEO and Co-Founder for insights into our $100B market opportunity, ongoing market traction, and future projections.

June 4, 2025

Advantages Of Circles Over "Big Data" RWE

Discover how Circles transform Big Data RWE by providing transparent, high-integrity insights directly from trusted sources. Say goodbye to fragmented, costly data and unlock meaningful, clinically relevant information while empowering physicians.

June 3, 2025

Peptides In Modern Medicine: Establishing Safety and Efficacy

Peptides are revolutionizing clinical diagnosis and treatment with their high selectivity and favorable side effect profiles. Here are some key insights:

RegenMed LLC Logo
Scroll Up Arrow

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

Forward looking statements were included here that the Company believes to be accurate given the current information. They involve known and unknown risks, uncertainties and other important factors which if changed may affect the outcome(s).

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Suite 950, Birmingham, AL 35242., is the Intermediary for this offering and is not an affiliate of or connected with the Issuer.  Please check our background on FINRA's BrokerCheck.
DealMaker Securities LLC does not make investment recommendations.
DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.
DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment.
DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.
DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.

Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

Copyright © 2025. RegenMed, Inc. All rights reserved.